17 May 2016 - VM BioPharma, the United States division of ViroMed, today announced that the U.S. FDA has granted fast track designation for the company's lead investigational drug, VM202, a Phase 2 novel gene therapy for the potential treatment of Amyotrophic Lateral Sclerosis (ALS).

ViroMed is anticipating the publication of data from the Phase 1/2 trial of VM202 in ALS in the second half of the year. The primary outcome of the trial was the safety and tolerability of VM202, and measures of the ALS functional rating scale and other efficacy parameters were studied as secondary outcomes.

For more details, go to: http://viromed.co.kr/bbs/bbsView.php?code=bbs_pr&bbs_id=0&id=75